Pandemic & Infectious Disease — 2026-03-30
The U.S. measles crisis continues to accelerate, with more than 1,500 confirmed cases and 16 active outbreaks documented so far in 2026 — tracking toward a multi-decade high. Pfizer and Valneva's Lyme disease vaccine candidate remains in the regulatory spotlight after Phase 3 results showing over 70% efficacy, with the companies planning to file for FDA approval. Meanwhile, a new Lancet commission is urging global leaders to prioritize viral spillover prevention ahead of the 2026 UN High-Level Meeting on pandemic preparedness.
Pandemic & Infectious Disease — 2026-03-30
Active Outbreak Tracker
Measles — United States
- Status: Over 1,500 confirmed cases across 16 active outbreaks nationwide in 2026
- Key Development: The U.S. measles case count continues to climb in 2026, with NBC News and U.S. News both tracking what may become one of the worst measles years in modern American history. Case counts already surpassed a 34-year high in 2025 and the current trajectory shows no sign of slowing. CDC is updating case counts weekly.
- Response: CDC is maintaining active surveillance and publishing weekly updates. Public health officials continue to urge vaccination as the primary preventive measure; MMR vaccine remains highly effective against all current circulating strains.
Respiratory Viruses (COVID-19, Influenza, RSV) — United States
- Status: CDC is monitoring COVID-19, influenza, and RSV epidemic trends nationally and by state; the agency has indicated it does not anticipate producing additional outlook updates for the remainder of the 2025–2026 respiratory season, suggesting activity is winding down.
- Key Development: The CDC's Center for Forecasting and Outbreak Analytics (CFA) is publishing real-time Rt (effective reproduction number) estimates for COVID-19, influenza, and RSV across U.S. states. Updated as of late March 2026, the data reflect current epidemic trends heading into spring.
- Response: CDC's respiratory illness data channel is being updated continuously. The agency's qualitative seasonal outlook team has assessed that major surge risk for this respiratory season is diminishing.
Dengue Fever — Peru / Climate Risk Zones Including Florida
- Status: A record-breaking dengue outbreak in Peru — linked to El Niño-driven extreme weather — has drawn renewed concern from U.S. researchers monitoring climate-driven disease spread into Florida and the Gulf Coast.
- Key Development: A newly published study connects Peru's historic dengue surge to climate-driven extreme weather patterns, specifically El Niño cycles that expand Aedes mosquito habitat. Researchers warn that similar conditions could accelerate local dengue transmission in Florida, where cases of locally acquired dengue have already been recorded in recent years.
- Response: Public health authorities are being urged to incorporate climate projections into vector-borne disease surveillance and preparedness planning. The study has implications for how Florida's health agencies model future dengue risk scenarios.
Vaccine & Treatment Pipeline
- VLA15 / "Lyme vaccine" (Pfizer & Valneva): Phase 3 VALOR ("Vaccine Against Lyme for Outdoor Recreationists") trial results show over 70% efficacy — approximately 70–73% — in preventing Lyme disease in individuals aged 5 and older. Despite falling short of its primary statistical endpoint due to fewer-than-expected Lyme cases in the trial period, Pfizer and Valneva announced plans to pursue FDA approval. The six-strain vaccine candidate is being positioned as the first Lyme disease vaccine to reach approval in a generation.
- TB Vaccine & MDR-TB Treatment Candidates (Multiple Developers): Phase III trials targeting tuberculosis vaccines and multidrug-resistant TB (MDR-TB) treatments remain among the most closely watched pipelines in 2026. GlobalData epidemiologists project TB cases across 16 major markets will reach 4.5 million by 2033, underscoring the urgency of regulatory progress this year.
- Multiple Therapeutics & Vaccines (Various): The 2026 pipeline of prospective regulatory filings includes a range of infectious disease therapeutics and vaccines expected to report Phase 3 data or seek regulatory approval this year. Contagion Live's tracker highlights this as a particularly active year for filings across antiviral and antibacterial categories.
Expert Analysis
A major new scientific commission published in The Lancet this week is calling for viral spillover prevention to be elevated to the top of the global health agenda ahead of the 2026 United Nations High-Level Meeting on pandemic prevention, preparedness, and response. The Lancet–PPATS Commission on Prevention of Viral Spillover argues that reducing the risk of the next pandemic requires a fundamental shift toward primary prevention — stopping viruses from jumping from animals to humans in the first place — rather than relying solely on reactive containment measures after spillover events occur.
The commission's abstract, published four days ago, frames spillover prevention as an underinvested and underrepresented dimension of global health security. While post-spillover tools such as vaccines, antivirals, and surveillance systems have received the bulk of pandemic preparedness funding, the commission contends that addressing the ecological and behavioral drivers of zoonotic spillover — including deforestation, wildlife trade, and intensive animal agriculture — is essential to reducing pandemic risk at its source.
The timing of the Lancet commission is significant: global leaders are expected to gather at the UN for high-level discussions on pandemic preparedness later in 2026, and the scientific community appears to be signaling that prevention frameworks must be broadened beyond detection and response. The commission's position aligns with a growing body of evidence that the majority of emerging infectious diseases with epidemic potential — including COVID-19, Ebola, and novel influenza strains — originate in animal reservoirs before crossing into human populations.
Global Health Security
UN High-Level Meeting on Pandemic Preparedness (Upcoming 2026): The Lancet–PPATS Commission is actively lobbying for spillover prevention language to be embedded in the final agreements at the upcoming UN High-Level Meeting on pandemic prevention, preparedness, and response. The commission's publication this week represents an organized scientific effort to shape policy outcomes at the meeting, with a particular focus on primary prevention and upstream risk reduction.
HIV Program Sustainability Concerns — Global: The George W. Bush Presidential Center's March 25 Global Health Update flags that recent U.S. Congressional debates over disease research funding could affect the future of HIV response programs. Commentary published in the Journal of the International AIDS Society notes that while new HIV infections have declined in many regions, sustaining progress will depend on countries' ability to integrate HIV services into broader health systems — and maintain funding commitments.
Lyme Disease Vaccine Regulatory Pathway: With Lyme disease season approaching in the northeastern United States, Pfizer and Valneva's regulatory filing plans for their Phase 3 VALOR candidate represent a notable vaccine policy milestone. If approved, the vaccine would be the first licensed Lyme disease vaccine in the U.S. in over two decades, filling a significant gap in tick-borne disease prevention — particularly as Lyme cases have surged in the Hudson Valley and across New England.
What to Watch Next
-
Lyme Disease Vaccine FDA Filing: Pfizer and Valneva are expected to formally submit their regulatory dossier for the VALOR vaccine in the coming months. The FDA's review timeline and any advisory committee hearings will be a key milestone to track — especially as tick season accelerates in the Northeast. Approval would mark the return of a Lyme vaccine to the U.S. market for the first time since 2002.
-
U.S. Measles Outbreak Trajectory: With over 1,500 cases and 16 outbreaks already recorded in the first months of 2026, public health officials will be watching weekly CDC case counts closely. If the current pace continues, 2026 could surpass 2025's 34-year high — putting renewed pressure on local vaccination campaigns and school immunization policies.
-
2026 UN High-Level Meeting on Pandemic Preparedness: As the Lancet commission's new report makes clear, the scientific community is mobilizing around the upcoming UN meeting. The outcome of negotiations — particularly whether spillover prevention and primary pandemic risk reduction are formally incorporated into global commitments — will shape the international health security agenda for years to come.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Create your own signal
Describe what you want to know, and AI will curate it for you automatically.
Create SignalPowered by
